You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFelbamate
Accession NumberDB00949  (APRD00505)
TypeSmall Molecule
GroupsApproved
Description

Felbamate is an anticonvulsant drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.

Structure
Thumb
Synonyms
2-Phenyl-1,3-propanediol dicarbamate
Carbamic acid 2-phenyltrimethylene ester
Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester
Felbamate
Felbamato
Felbamatum
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Felbamatesuspension600 mg/5mLoralWallace Pharmaceuticals Inc.2011-11-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Felbamatetablet600 mg/1oralWallace Pharmaceuticals Inc.2011-11-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Felbamatetablet400 mg/1oralWallace Pharmaceuticals Inc.2011-11-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Felbatoltablet400 mg/1oralMeda Pharmaceuticals Inc.1993-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Felbatolsuspension600 mg/5mLoralMeda Pharmaceuticals Inc.1993-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Felbatoltablet600 mg/1oralMeda Pharmaceuticals Inc.1993-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Felbamatetablet400 mg/1oralMarlex Pharmaceuticals Inc2015-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Felbamatetablet600 mg/1oralMylan Pharmaceuticals Inc.2016-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Felbamatetablet400 mg/1oralMylan Pharmaceuticals Inc.2016-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Felbamatetablet600 mg/1oralCarilion Materials Management2011-09-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Felbamatetablet600 mg/1oralAmneal Pharmaceuticals of New York, LLC2011-09-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Felbamatetablet400 mg/1oralAmneal Pharmaceuticals of New York, LLC2011-09-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Felbamatesuspension600 mg/5mLoralAmneal Pharmaceuticals of New York, LLC2011-12-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Felbamatetablet600 mg/1oralMarlex Pharmaceuticals Inc2015-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
FelbamylNot Available
TaloxaNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIX72RBB02N8
CAS number25451-15-4
WeightAverage: 238.2399
Monoisotopic: 238.095356946
Chemical FormulaC11H14N2O4
InChI KeyInChIKey=WKGXYQFOCVYPAC-UHFFFAOYSA-N
InChI
InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)
IUPAC Name
3-(carbamoyloxy)-2-phenylpropyl carbamate
SMILES
NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassNot Available
Direct ParentBenzene and substituted derivatives
Alternative Parents
Substituents
  • Monocyclic benzene moiety
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
PharmacodynamicsFelbamate is an antiepileptic indicated as monotherapy or as an adjunct to other anticonvulsants for the treatment of partial seizures resulting from epilepsy. Receptor-binding studies in vitro indicate that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding, and is devoid of activity at the MK-801 receptor binding site of the NMDA receptor-ionophore complex. However, felbamate does interact as an antagonist at the strychnine-insensitive glycine recognition site of the NMDA receptor-ionophore complex.
Mechanism of actionThe mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. In vitro receptor binding studies suggest that felbamate may be an antagonist at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate (NMDA) receptor-ionophore complex. Antagonism of the NMDA receptor glycine binding site may block the effects of the excitatory amino acids and suppress seizure activity. Animal studies indicate that felbamate may increase the seizure threshold and may decrease seizure spread. It is also indicated that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding.
Absorption>90%
Volume of distribution
  • 756±82 mL/kg
Protein binding20-36%
Metabolism

Hepatic

SubstrateEnzymesProduct
Felbamate
2-Phenyl-1,3-propanediol monocarbamateDetails
Felbamate
p-HydroxyfelbamateDetails
Felbamate
2-HydroxyfelbamateDetails
2-Phenyl-1,3-propanediol monocarbamate
3-Carbamoyl-2-phenylpropionaldehydeDetails
3-Carbamoyl-2-phenylpropionaldehyde
Not Available
AtropaldehydeDetails
3-Carbamoyl-2-phenylpropionaldehyde
Not Available
4-Hydroxy-5-phenyltetrahydro-1,3-oxazin-2-oneDetails
3-Carbamoyl-2-phenylpropionaldehyde
3-Carbamoyl-2-phenylpropionic acidDetails
4-Hydroxy-5-phenyltetrahydro-1,3-oxazin-2-one
5-Phenyl-1,3-oxazinane-2,4-dioneDetails
5-Phenyl-1,3-oxazinane-2,4-dione
Not Available
3-Carbamoyl-2-phenylpropionic acidDetails
Route of eliminationNot Available
Half life20-23 hours
Clearance
  • 26 +/- 3 mL/hr/kg [single 1200 mg dose]
  • 30 +/- 8 mL/hr/kg [multiple daily doses of 3600 mg]
ToxicityLD50=5000 mg/kg (Orally in rats)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9544
Blood Brain Barrier+0.9805
Caco-2 permeable-0.6324
P-glycoprotein substrateNon-substrate0.783
P-glycoprotein inhibitor INon-inhibitor0.9551
P-glycoprotein inhibitor IINon-inhibitor0.932
Renal organic cation transporterNon-inhibitor0.9039
CYP450 2C9 substrateNon-substrate0.9009
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7942
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9184
CYP450 2D6 inhibitorInhibitor0.7126
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9271
Ames testNon AMES toxic0.7602
CarcinogenicityNon-carcinogens0.8338
BiodegradationNot ready biodegradable0.8068
Rat acute toxicity1.7095 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9872
hERG inhibition (predictor II)Non-inhibitor0.9786
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Meda pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Suspensionoral600 mg/5mL
Tabletoral400 mg/1
Tabletoral600 mg/1
Prices
Unit descriptionCostUnit
Felbatol 600 mg tablet3.1USD tablet
Felbatol 400 mg tablet2.71USD tablet
Felbatol 600 mg/5ml Suspension1.43USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States49786801992-09-262009-09-26
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point151.5 °CPhysProp
water solubilitySlightly soluble in waterNot Available
logP0.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.742 mg/mLALOGPS
logP0.56ALOGPS
logP0.68ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)14.98ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area104.64 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity59.59 m3·mol-1ChemAxon
Polarizability23.52 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-mz00000000-673caaab3dded596924cView in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Leppik IE, Dreifuss FE, Pledger GW, Graves NM, Santilli N, Drury I, Tsay JY, Jacobs MP, Bertram E, Cereghino JJ, et al.: Felbamate for partial seizures: results of a controlled clinical trial. Neurology. 1991 Nov;41(11):1785-9. Pubmed
External Links
ATC CodesN03AX10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (47.1 KB)
Interactions
Drug Interactions
Drug
AmobarbitalThe serum concentration of Amobarbital can be increased when it is combined with Felbamate.
AprepitantThe serum concentration of Felbamate can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Felbamate.
AzelastineFelbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Felbamate.
BexaroteneThe serum concentration of Felbamate can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Felbamate can be decreased when it is combined with Bosentan.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
BuprenorphineFelbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
ButabarbitalThe serum concentration of Butabarbital can be increased when it is combined with Felbamate.
ButethalThe serum concentration of Butethal can be increased when it is combined with Felbamate.
CarbamazepineThe serum concentration of Felbamate can be decreased when it is combined with Carbamazepine.
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Felbamate.
CitalopramFelbamate may increase the QTc-prolonging activities of Citalopram.
ConivaptanThe serum concentration of Felbamate can be increased when it is combined with Conivaptan.
DabrafenibThe serum concentration of Felbamate can be decreased when it is combined with Dabrafenib.
DasatinibThe serum concentration of Felbamate can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Felbamate can be decreased when it is combined with Deferasirox.
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Felbamate.
DofetilideFelbamate may increase the QTc-prolonging activities of Dofetilide.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
EthanolFelbamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Felbamate.
FluconazoleThe metabolism of Felbamate can be decreased when combined with Fluconazole.
FosaprepitantThe serum concentration of Felbamate can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Felbamate can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Felbamate can be increased when it is combined with Fusidic Acid.
GoserelinFelbamate may increase the QTc-prolonging activities of Goserelin.
HeptabarbitalThe serum concentration of Heptabarbital can be increased when it is combined with Felbamate.
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Felbamate.
HydrocodoneFelbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
IdelalisibThe serum concentration of Felbamate can be increased when it is combined with Idelalisib.
IvacaftorThe serum concentration of Felbamate can be increased when it is combined with Ivacaftor.
LeuprolideFelbamate may increase the QTc-prolonging activities of Leuprolide.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Felbamate.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Felbamate.
LuliconazoleThe serum concentration of Felbamate can be increased when it is combined with Luliconazole.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
Medroxyprogesterone AcetateThe serum concentration of Medroxyprogesterone Acetate can be decreased when it is combined with Felbamate.
MefloquineThe therapeutic efficacy of Felbamate can be decreased when used in combination with Mefloquine.
MethohexitalThe serum concentration of Methohexital can be increased when it is combined with Felbamate.
MethotrimeprazineFelbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MetyrosineFelbamate may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Felbamate can be decreased when used in combination with Mianserin.
MifepristoneThe serum concentration of Felbamate can be increased when it is combined with Mifepristone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
MirtazapineFelbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MitotaneThe serum concentration of Felbamate can be decreased when it is combined with Mitotane.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
NelfinavirThe metabolism of Felbamate can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Felbamate can be increased when it is combined with Netupitant.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Felbamate.
NorethindroneThe serum concentration of Norethindrone can be decreased when it is combined with Felbamate.
OrlistatThe serum concentration of Felbamate can be decreased when it is combined with Orlistat.
OrphenadrineFelbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PalbociclibThe serum concentration of Felbamate can be increased when it is combined with Palbociclib.
ParaldehydeFelbamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Felbamate is combined with Paroxetine.
PentobarbitalThe serum concentration of Pentobarbital can be increased when it is combined with Felbamate.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
PhenobarbitalThe serum concentration of Felbamate can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Felbamate.
PramipexoleFelbamate may increase the sedative activities of Pramipexole.
PrimidoneThe serum concentration of Primidone can be increased when it is combined with Felbamate.
RopiniroleFelbamate may increase the sedative activities of Ropinirole.
RotigotineFelbamate may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Felbamate.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Felbamate.
SecobarbitalThe serum concentration of Secobarbital can be increased when it is combined with Felbamate.
SiltuximabThe serum concentration of Felbamate can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Felbamate can be increased when it is combined with Simeprevir.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
St. John's WortThe serum concentration of Felbamate can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Felbamate can be increased when it is combined with Stiripentol.
SuvorexantFelbamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
ThalidomideFelbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TocilizumabThe serum concentration of Felbamate can be decreased when it is combined with Tocilizumab.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Felbamate.
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Felbamate.
ZolpidemFelbamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Taking it after a meal may reduce the incidence of adverse effects.

Targets

1. Glutamate receptor ionotropic, NMDA 2B

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Glutamate receptor ionotropic, NMDA 2B Q13224 Details

References:

  1. Kleckner NW, Glazewski JC, Chen CC, Moscrip TD: Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action. J Pharmacol Exp Ther. 1999 May;289(2):886-94. Pubmed
  2. Harty TP, Rogawski MA: Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res. 2000 Mar;39(1):47-55. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  4. Chang HR, Kuo CC: Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45. Epub 2008 Feb 27. Pubmed
  5. Luszczki JJ, Danysz W, Czuczwar SJ: Interactions of MRZ 2/576 with felbamate, lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology. 2008;81(3):259-65. Epub 2008 Feb 4. Pubmed

2. Glutamate receptor ionotropic, NMDA 3A

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Glutamate receptor ionotropic, NMDA 3A Q8TCU5 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

3. Glutamate receptor ionotropic, NMDA 2A

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Glutamate receptor ionotropic, NMDA 2A Q12879 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Enzymes

1. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Williams DA, Foye WO, Lemke TL. Foye’s principles of medicinal chemistry. Lippincott Williams & Wilkins; 2002.
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inducer

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 2E1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2E1 P05181 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:12